Global Targeted-protein Degradation Therapeutics Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI09243494

Publication Date:

September 24, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Targeted-protein Degradation Therapeutics market size was valued at US$ 1107.4 million in 2023. With growing demand in downstream market, the Targeted-protein Degradation Therapeutics is forecast to a readjusted size of US$ 1719 million by 2030 with a CAGR of 6.5% during review period.
The research report highlights the growth potential of the global Targeted-protein Degradation Therapeutics market. Targeted-protein Degradation Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Targeted-protein Degradation Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Targeted-protein Degradation Therapeutics market.
Targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway.
The Protein Degradation Therapy market has gained momentum as a promising approach in drug development. This innovative strategy aims to target disease-causing proteins by facilitating their degradation within cells. Proteins that contribute to diseases like cancer and neurodegenerative disorders can be selectively broken down using small molecules known as proteolysis-targeting chimeras (PROTACs) or other protein degraders. This approach offers advantages over traditional inhibition methods, potentially leading to more effective treatments with reduced side effects. As researchers delve into protein-protein interactions and cellular mechanisms, the Protein Degradation Therapy market is expanding, presenting opportunities to address previously challenging diseases and advance precision medicine. Clinical progress and continued research in this field are expected to shape the future of therapeutic interventions.
Key Features:
The report on Targeted-protein Degradation Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Targeted-protein Degradation Therapeutics market. It may include historical data, market segmentation by Type (e.g., ARV-110, ARV-471), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Targeted-protein Degradation Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Targeted-protein Degradation Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Targeted-protein Degradation Therapeutics industry. This include advancements in Targeted-protein Degradation Therapeutics technology, Targeted-protein Degradation Therapeutics new entrants, Targeted-protein Degradation Therapeutics new investment, and other innovations that are shaping the future of Targeted-protein Degradation Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Targeted-protein Degradation Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Targeted-protein Degradation Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Targeted-protein Degradation Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Targeted-protein Degradation Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Targeted-protein Degradation Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Targeted-protein Degradation Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Targeted-protein Degradation Therapeutics market.
Market Segmentation:
Targeted-protein Degradation Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
ARV-110
ARV-471
Other
Segmentation by application
Cancer
Neuroscience
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arvinas
Nurix Therapeutics
Kymera Therapeutics
C4 Therapeutics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Targeted-protein Degradation Therapeutics Market Size 2019-2030
2.1.2 Targeted-protein Degradation Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Targeted-protein Degradation Therapeutics Segment by Type
2.2.1 ARV-110
2.2.2 ARV-471
2.2.3 Other
2.3 Targeted-protein Degradation Therapeutics Market Size by Type
2.3.1 Targeted-protein Degradation Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Targeted-protein Degradation Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Targeted-protein Degradation Therapeutics Segment by Application
2.4.1 Cancer
2.4.2 Neuroscience
2.4.3 Other
2.5 Targeted-protein Degradation Therapeutics Market Size by Application
2.5.1 Targeted-protein Degradation Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Targeted-protein Degradation Therapeutics Market Size Market Share by Application (2019-2024)
3 Targeted-protein Degradation Therapeutics Market Size by Player
3.1 Targeted-protein Degradation Therapeutics Market Size Market Share by Players
3.1.1 Global Targeted-protein Degradation Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Targeted-protein Degradation Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Targeted-protein Degradation Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Targeted-protein Degradation Therapeutics by Regions
4.1 Targeted-protein Degradation Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Targeted-protein Degradation Therapeutics Market Size Growth (2019-2024)
4.3 APAC Targeted-protein Degradation Therapeutics Market Size Growth (2019-2024)
4.4 Europe Targeted-protein Degradation Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Targeted-protein Degradation Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Targeted-protein Degradation Therapeutics Market Size by Country (2019-2024)
5.2 Americas Targeted-protein Degradation Therapeutics Market Size by Type (2019-2024)
5.3 Americas Targeted-protein Degradation Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted-protein Degradation Therapeutics Market Size by Region (2019-2024)
6.2 APAC Targeted-protein Degradation Therapeutics Market Size by Type (2019-2024)
6.3 APAC Targeted-protein Degradation Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Targeted-protein Degradation Therapeutics by Country (2019-2024)
7.2 Europe Targeted-protein Degradation Therapeutics Market Size by Type (2019-2024)
7.3 Europe Targeted-protein Degradation Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Targeted-protein Degradation Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Targeted-protein Degradation Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Targeted-protein Degradation Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Targeted-protein Degradation Therapeutics Market Forecast
10.1 Global Targeted-protein Degradation Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Targeted-protein Degradation Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Targeted-protein Degradation Therapeutics Forecast
10.1.3 APAC Targeted-protein Degradation Therapeutics Forecast
10.1.4 Europe Targeted-protein Degradation Therapeutics Forecast
10.1.5 Middle East & Africa Targeted-protein Degradation Therapeutics Forecast
10.2 Americas Targeted-protein Degradation Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Targeted-protein Degradation Therapeutics Market Forecast
10.2.2 Canada Targeted-protein Degradation Therapeutics Market Forecast
10.2.3 Mexico Targeted-protein Degradation Therapeutics Market Forecast
10.2.4 Brazil Targeted-protein Degradation Therapeutics Market Forecast
10.3 APAC Targeted-protein Degradation Therapeutics Forecast by Region (2025-2030)
10.3.1 China Targeted-protein Degradation Therapeutics Market Forecast
10.3.2 Japan Targeted-protein Degradation Therapeutics Market Forecast
10.3.3 Korea Targeted-protein Degradation Therapeutics Market Forecast
10.3.4 Southeast Asia Targeted-protein Degradation Therapeutics Market Forecast
10.3.5 India Targeted-protein Degradation Therapeutics Market Forecast
10.3.6 Australia Targeted-protein Degradation Therapeutics Market Forecast
10.4 Europe Targeted-protein Degradation Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Targeted-protein Degradation Therapeutics Market Forecast
10.4.2 France Targeted-protein Degradation Therapeutics Market Forecast
10.4.3 UK Targeted-protein Degradation Therapeutics Market Forecast
10.4.4 Italy Targeted-protein Degradation Therapeutics Market Forecast
10.4.5 Russia Targeted-protein Degradation Therapeutics Market Forecast
10.5 Middle East & Africa Targeted-protein Degradation Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Targeted-protein Degradation Therapeutics Market Forecast
10.5.2 South Africa Targeted-protein Degradation Therapeutics Market Forecast
10.5.3 Israel Targeted-protein Degradation Therapeutics Market Forecast
10.5.4 Turkey Targeted-protein Degradation Therapeutics Market Forecast
10.5.5 GCC Countries Targeted-protein Degradation Therapeutics Market Forecast
10.6 Global Targeted-protein Degradation Therapeutics Forecast by Type (2025-2030)
10.7 Global Targeted-protein Degradation Therapeutics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Arvinas
11.1.1 Arvinas Company Information
11.1.2 Arvinas Targeted-protein Degradation Therapeutics Product Offered
11.1.3 Arvinas Targeted-protein Degradation Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Arvinas Main Business Overview
11.1.5 Arvinas Latest Developments
11.2 Nurix Therapeutics
11.2.1 Nurix Therapeutics Company Information
11.2.2 Nurix Therapeutics Targeted-protein Degradation Therapeutics Product Offered
11.2.3 Nurix Therapeutics Targeted-protein Degradation Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Nurix Therapeutics Main Business Overview
11.2.5 Nurix Therapeutics Latest Developments
11.3 Kymera Therapeutics
11.3.1 Kymera Therapeutics Company Information
11.3.2 Kymera Therapeutics Targeted-protein Degradation Therapeutics Product Offered
11.3.3 Kymera Therapeutics Targeted-protein Degradation Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Kymera Therapeutics Main Business Overview
11.3.5 Kymera Therapeutics Latest Developments
11.4 C4 Therapeutics
11.4.1 C4 Therapeutics Company Information
11.4.2 C4 Therapeutics Targeted-protein Degradation Therapeutics Product Offered
11.4.3 C4 Therapeutics Targeted-protein Degradation Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 C4 Therapeutics Main Business Overview
11.4.5 C4 Therapeutics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂